natgillin/translations-raw huggingface dataset:
Milaxyn Plus, Strantel Plus, Prazical Plus, Voxical Plus, Exitel Plus, Cazitel Plus and Prazitel Plus (and associated names) are veterinary medicinal products as tablets for dogs containing 50 mg praziquantel, 50 mg pyrantel (equivalent to 144 mg pyrantel embonate) and 150 mg of febantel. 
Milaxyn Plus, Strantel Plus, Prazical Plus, Voxical Plus, Exitel Plus, Cazitel Plus in Prazitel Plus (ter povezana imena) so zdravila za uporabo v veterinarski medicine v obliki tablet za pse, ki vsebujejo 50 mg prazikvantela, 50 mg pirantelija (kar je enako 144 mg pirantelijevega embonata) in 150 mg febantela.
Based on the evaluation of the currently available data, the CVMP considered that the overall benefitrisk profile for Milaxyn Plus, Strantel Plus, Prazical Plus, Voxical Plus and associated names (authorised via Mutual Recognition Procedure No IE/V/0272-0275/001/MR) remains positive subject to variation of the marketing authorisations in accordance with the recommended changes to the product information. 
Na podlagi ocene trenutno razpoložljivih podatkov je CVMP menil, da je splošno razmerje med koristmi in tveganji za zdravila Milaxyn Plus, Strantel Plus, Prazical Plus, Voxical Plus in povezana imena (odobrena s postopkom medsebojnega priznavanja št. IE/V/0272-0275/001/MR) ostaja pozitivno pod pogojem, da se dovoljenje za promet z zdravilom spremeni v skladu s priporočenimi spremembami
Strantel Plus, Prazical Plus, Voxical Plus, Exitel Plus, Cazitel Plus and Prazitel Plus and associated names 
za zdravila Milaxyn Plus, Strantel Plus, Prazical Plus, Voxical Plus, Exitel Plus, Cazitel Plus in Prazitel Plus ter povezana imena
terms of the marketing authorisations for Milaxyn Plus, Strantel Plus, Prazical Plus and Voxical Plus (and associated names) (authorised via Mutual Recognition Procedure No IE/V/0272-0275/001/MR) and the maintenance of the marketing authorisations for Prazitel Plus, Exitel Plus and Cazitel Plus (and associated names) (authorised via Mutual Recognition Procedure No IE/V/0241-0243/001/MR). 
Odbor je zato 7. marca 2012 sprejel pozitivno mnenje, v katerem je priporočil spremembo pogojev dovoljenj za promet za zdravila Milaxyn Plus, Strantel Plus, Prazical Plus in Voxical Plus (ter povezana imena) (odobrena s postopkom medsebojnega priznavanja št. IE/V/02720275/001/MR) ter ohranitev dovoljenj za promet z zdravili Prazitel Plus, Exitel Plus in Cazitel Plus (ter povezana imena) (odobrena s postopkom medsebojnega priznavanja št. IE/V/0241-0243/001/MR).
Opinion following an Article 34F F referral for Milaxyn Plus, Strantel Plus, Prazical Plus, Voxical Plus, Exitel Plus, Cazitel Plus and Prazitel Plus and associated names EMA/289985/2012 
Mnenje v zvezi z napotitvijo v skladu s členom 34F F za zdravila Milaxyn Plus, Strantel Plus, Prazical Plus, Voxical Plus, Exitel Plus, Cazitel Plus in Prazitel Plus ter povezana imena stran 2/2
• it is used in children and adolescents aged 6-17 years. 
• uporablja se pri otrocih in mladostnikih, starih 6-17 let.
Abuse, misuse, and diversion 
Napačna uporaba, zloraba in preusmeritev
• it is not indicated in all children with ADHD. 
• ni indicirano pri vseh otrocih z ADHD.
• it is used only after when another medicine called methylphenidate was not sufficiently effective. 
• uporablja se le, če drugo zdravilo, imenovano metilfenidat, ni bilo dovolj učinkovito.
A comprehensive treatment programme typically includes psychological, educational and social measures. 
Obširni program zdravljenja običajno vključuje psihološke, izobraževalne in socialne ukrepe.
WHAT DEXAMED IS AND WHAT IT IS USED FOR 
KAJ JE ZDRAVILO DEXAMED IN ZA KAJ GA UPORABLJAMO Za kaj se uporablja
Diagnosis should be made according to DSM-5 criteria or the guidelines in ICD-10 and should be based on a comprehensive multidisciplinary evaluation of the patient. 
Diagnozo je treba postaviti v skladu s kriteriji DSM-5 ali smernicami ICD-10; temeljiti mora na podlagi obširne multidisciplinarne ocene bolnika.
Note: These amendments are to be incorporated to the valid Summary of Product Characteristics, labelling and package leaflet which are the final versions achieved during the Coordination group procedure 
Opomba: Spremembe se vključijo v veljavni povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo, ki so končne različice, dosežene v postopku koordinacijske skupine
4.1 Therapeutic indications [The wording of this section should read as follows] 
4.1 Terapevtske indikacije [Besedilo tega poglavja naj se glasi kot sledi]
Dexamfetamine possesses a high potential to cause dependency and has been/is frequently abused. 
Deksamfetamin ima visok potencial za povzročanje odvisnosti in so ga/ga pogosto zlorabljajo.
Dexamfetamine is not indicated in all children with ADHD and the decision to use dexamfetamine must be based on a very thorough assessment of the severity and chronicity of the child's symptoms in relation to the child's age and potential for abuse, misuse or diversion. 
Deksamfetamin ni indiciran pri vseh otrocih z ADHD; odločitev o uporabi deksamfetamina mora temeljiti na zelo temeljiti oceni resnosti in kroničnosti otrokovih simptomov ob upoštevanju otrokove starosti in možnosti za napačno uporabo, zlorabo, ali preusmeritev uporabe.
Treatment should be under the supervision of a specialist in childhood and/or adolescent behavioural disorders. 
Zdravljenje mora potekati pod nadzorom specialista vedenjskih motenj pri otrocih in/ali mladostnikih.
[The following sentence should be added in its place] The risk is generally greater for short acting stimulants than for corresponding long-acting products (see section 4.1). 
Tveganje je na splošno večje za hitrodelujoče stimulante, kot za ustrezna dolgodelujoča zdravila (glejte poglavje 4.1).
Dexamed is used to treat attention-deficit/hyperactivity disorder (ADHD). 
Zdravilo Dexamed se uporablja za zdravljenje motnje pomanjkljive pozornosti s hiperaktivnostjo (ADHD, attention-deficit/hyperactivity disorder).
• It should be used as part of a treatment programme which typically includes psychological, 
• uporablja se kot del programa zdravljenja, ki običajno vključuje psihološke, izboraževalne in socialne ukrepe.
[These bullet points should read as follows] 
[Te točke morajo biti navedene kot sledi]
Package leaflet: Information for the patient Dexamed 5 mg tablets 
Navodilo za uporabo Dexamed 5 mg tablete deksamfetaminijev sulfat
[The following wording should be added at the end of this section] 
[Spodnje besedilo se doda na koncu tega poglavja]
Amendments to the summary of product characteristics and package leaflet 
Spremembe povzetka glavnih značilnosti zdravila in navodila za uporabo
[The wording below should be deleted] 
[Naslednje besedilo se briše]
Dexamfetamine is indicated as part of a comprehensive treatment programme for attentiondeficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17 years when response to previous methylphenidate treatment is considered clinically inadequate. 
Deksamfetamin je indicirano kot del obširnega programa zdravljenja motnje pomanjkljive pozornosti s hiperaktivnostjo (ADHD, attention deficit/hyperactivity disorder) pri otrocih in mladostnikih, starih 6 do
[The below wording should be inserted at the top of the document] 
[Spodnje besedilo se vstavi na začetku tega dokumenta]
What it is used for 
NAVODILO ZA UPORABO
This summary was last updated in 09-2007. 
Povzetek je bil nazadnje posodobljen 09-2007.
The marketing authorisation holder is Glaxo Group Ltd. 
Imetnik dovoljenja za promet z zdravilom je družba Glaxo Group Ltd.
The dose may be adjusted, depending on body weight. 
Odmerek se lahko prilagodi, odvisno od telesne mase.
The marketing authorisation was renewed on 21 March 2007. 
Dovoljenje za promet z zdravilom je bilo podaljšano 21. marca 2007.
For patients having surgery, the first dose should be given six hours after the end of the operation. 
Bolnikom, ki so prestali operacijo, se začetni odmerek daje šest ur po zaključku operacije.
Other information about Quixidar: 
Druge informacije o zdravilu Quixidar:
Blood clotting can be a problem when blood flow is disturbed in any way. 
Strjevanje krvi lahko predstavlja resno težavo, če je pretok krvi na kakršen koli način oviran.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) QUIXIDAR EPAR summary for the public 
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) QUIXIDAR Povzetek EPAR za javnost
For the full list of restrictions, see the Package Leaflet. 
Za celoten seznam omejitev glejte Navodilo za uporabo.
It can also be used in patients at high risk (because of their age or disease) when they have abdominal surgery, especially for cancer, or when they are forced to stay in bed because of an acute illness. 
Prav tako se ga lahko uporablja pri bolnikih, pri katerih obstaja povečano tveganje (zaradi njihove starosti ali bolezni) pri kirurških posegih v trebušni votlini, še posebej v primeru raka, ali pri bolnikih, ki so primorani ostati v postelji zaradi akutne bolezni.
In all studies, the main measure of effectiveness was the overall rate of thrombotic events (problems caused by blood clots). 
V vseh študijah je bilo glavno merilo skupna stopnja trombotičnih dogodkov (zapletov zaradi krvnih strdkov).
The European Commission granted a marketing authorisation valid throughout the European Union for Quixidar on 21 March 2002. 
Evropska komisija je dovoljenje za promet z zdravilom Quixidar, veljavno po celotni Evropski uniji, odobrila dne 21. marca 2002.
The main measure of effectiveness was the proportion of patients who died or had an ‘ischaemic event' (restriction of blood supply to an organ, including the heart). 
Glavno merilo učinkovitosti je bil delež bolnikov, ki so umrli ali so imeli „ishemični dogodek“ (omejitev dotoka krvi do organov, vključno do srca).
Treatment should be continued until the risk of VTE has been reduced, usually at least five to nine days after surgery. 
Z zdravljenjem je treba nadaljevati, dokler se tveganje za vensko tromboembolične dogodke ne zmanjša, navadno vsaj pet do devet dni po operaciji.
However, these results were insufficient to show whether Quixidar was more effective than unfractionated heparin or not. 
Vendar ti rezultati niso bili zadostni, da bi pokazali, da je zdravilo Quixidar bilo bolj učinkovito kot nefrakcionirani heparin.
For patients who have kidney problems, Quixidar may not be suitable, or the lower 1.5-mg dose may be used. 
Za bolnike, ki imajo težave s ledvicami, zdravilo Quixidar morda ni ustrezno, oziroma se lahko uporabi znižani, 1,5 mg odmerek.
The Committee recommended that Quixidar be given marketing authorisation. 
Zato je odbor priporočil, da se za zdravilo Quixidar podeli dovoljenje za promet.
As with other antithrombotic medicines, the most common side effect of Quixidar is bleeding. 
Kot pri vseh drugih antitrombotičnih zdravilih je najpogostejši neželeni učinek zdravila Quixidar krvavenje.
By using Quixidar after surgery, the risk of a blood clot forming is greatly reduced. 
Z uporabo zdravila Quixidar po operaciji se tveganje za nastanek krvnih strdkov močno zmanjša.
For more information, see the Summary of Product Characteristics (also part of the EPAR). 
Za več informacij glejte Povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
When this is blocked, no thrombin (another factor) can be produced, and no clot can be formed. 
Če je ta blokiran, se trombin (drugi faktor) ne more več tvoriti, zaradi česar tudi krvni strdki ne morejo več nastajati.
What benefit has Quixidar shown during the studies? 
Kakšne koristi je zdravilo Quixidar izkazalo med raziskavami?
What is the risk associated with Quixidar? 
Kakšna tveganja so povezana z zdravilom Quixidar?
Quixidar contains the active substance fondaparinux sodium (1.5, 2.5, 5, 7.5 or 10 mg per syringe). 
Quixidar vsebuje zdravilno učinkovino natrijev fondaparinuks (1,5 mg, 2,5 mg, 5 mg, 7,5 mg ali 10 mg na brizgo).
Quixidar is a solution for injection in a prefilled syringe. 
Zdravilo Quixidar je raztopina za injiciranje v napolnjeni injekcijski brizgi.
Quixidar is not recommended in patients who are about to undergo certain types of PCI. 
Zdravila Quixidar se ne priporoča bolnikom, ki so pred določenimi vrstami perkutane koronarne intervencije.
Quixidar is an anticoagulant; it prevents the blood from coagulating (clotting). 
Zdravilo Quixidar je antikoagulant - preprečuje koagulacijo (strjevanje) krvi.
Quixidar was at least as effective as enoxaparin in preventing death or an ischaemic event in patients with unstable angina or myocardial infarction without ST segment elevation, with around 5% of the patients in each group had died or had an ischaemic event after nine days. 
Zdravilo Quixidar je bilo vsaj toliko učinkovito kot enoksaparin pri preprečevanju smrti ali ishemičnih dogodkov pri bolnikih z nestabilno angino pektoris ali miokardnim infarktom z dvigom spojnice ST, pri čemer je približno 5 % bolnikov v vsaki skupini umrlo ali imelo ishemični dogodek po devetih dneh.
For the full list of all side effects reported with Quixidar, see the Package Leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Quixidar, glejte Navodilo za uporabo.
It was also compared with placebo (a dummy treatment) when looking at patients with an acute illness (839 patients) and patients treated for an additional 24 days following hip fracture surgery (656 patients). 
Prav tako so ga primerjali s placebom (zdravljenje brez zdravilne učinkovine), in sicer pri bolnikih z akutno boleznijo (839 bolnikov) in pri bolnikih, ki so bili zdravljeni nadaljnjih 24 dni po operaciji zloma kolka (656 bolnikov).
The active ingredient in Quixidar, fondaparinux sodium, stops one of the substances (factors) that are involved in the clotting of blood, Factor Xa. 
Zdravilna učinkovina natrijev fondaparinuks, ki se nahaja v zdravilu Quixidar, blokira eno od snovi (faktorjev), ki sodelujejo pri strjevanju krvi, in sicer faktor Xa.
In the study of myocardial infarction with ST segment elevation, Quixidar reduced the risk of death or another heart attack by 14% after 30 days, compared to standard care. 
Pri študiji miokardnega infarkta z dvigom spojnice ST je zdravilo Quixidar v primerjavi s standardnim zdravljenjem zmanjšalo tvaganje smrti ali ponovnega srčnega napada za 14 % po 30 dneh.
The effectiveness of Quixidar has been studied for the prevention of and in the treatment of VTE. 
Učinkovitost zdravila Quixidar je bila preučevana z vidika preprečevanja in zdravljenja venskih tromboemboličnih dogodkov.
Why has Quixidar been approved? 
Zakaj je bilo zdravilo Quixidar odobreno?
The 2.5 mg strength is also used to treat patients with unstable angina (a type of chest pain that changes in severity) or who are having a myocardial infarction (heart attack): 
Odmerek jakosti 2,5 mg se uporablja tudi za zdravljenje bolnikov z nestabilno angino pektoris (vrsto bolečine v prsih, katere jakost se naglo spreminja) ali bolnikov, ki imajo miokardni infarkt (srčni napad):
Quixidar should not be used in people who may be hypersensitive (allergic) to fondaparinux sodium or any of the other ingredients, who might be bleeding already, who have acute bacterial endocarditis (an infection of the heart) or have severe kidney problems. 
Zdravila Quixidar se ne sme uporabljati pri osebah, ki so preobčutljive za (alergične na) natrijev fondaparinuks ali katerokoli drugo sestavino zdravila, ter pri osebah, ki krvavijo ali imajo akutni bakterijski endokarditis (okužbo srca) ali hude težave z ledvicami.
Quixidar has also been studied in two main studies of patients with unstable angina or myocardial infarction. 
Zdravilo Quixidar so raziskovali v dveh glavnih študijah bolnikov z nestabilno angino pektoris ali miokardnim infarktom.
By reducing blood clots, Quixidar can also help the flow of blood to the heart to be maintained in patients with angina or who are having a heart attack. 
Poleg zmanjševanja nastanka krvnih strdkov lahko zdravilo Quixidar pomaga bolnikom z angino pektoris ali bolnikom, ki imajo srčni napad, da ohranijo pretok krvi v srce.
In the prevention of VTEs, the recommended dose of Quixidar is 2.5 mg once a day by subcutaneous injection (under the skin). 
Za preprečevanje tromboemboličnih dogodkov je priporočeni odmerek zdravila Quixidar 2,5 mg enkrat dnevno, ki se daje s subkutano injekcijo (pod kožo).
The overall rate of thrombotic events in patients treated with Quixidar was significantly less than in patients treated with placebo or enoxaparin (for patients undergoing leg surgery), and was similar to that seen with enoxaparin (treatment of DVT), dalteparin or unfractionated heparin. 
Skupna stopnja trombotičnih dogodkov pri bolnikih, zdravljenih z zdravilom Quixidar, je bila znatno manjša kot pri bolnikih, zdravljenih s placebom ali enoksaparinom (pri bolnikih, operiranih na nogah), oziroma je bila podobna tisti, ugotovljeni pri uporabi enoksaparina (pri zdravljenju globoke venske tromboze), dalteparina ali nefrakcioniranega heparina.
The Committee for Medicinal Products for Human Use (CHMP) decided that Quixidar's benefits are greater than its risks in both the prevention and the treatment of VTEs, unstable angina and myocardial infarction. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je odločil, da so koristi zdravila Quixidar tako pri preprečevanju kot zdravljenju venskih trombotičnih dogodkov, nestabilne angine pektoris in miokardnega infarkta večje od z njim povezanih tveganj.
In the prevention studies, Quixidar was compared with other anticoagulants: enoxaparin (in hip or knee surgery; over 8,000 patients) or dalteparin (in abdominal surgery; 2,927 patients). 
V študijah za preprečevanje bolezni so zdravilo Quixidar primerjali z drugimi antikoagulanti: enoksaparinom (pri operacijah kolka ali kolena; več kot 8000 bolnikov) ali z dalteparinom (pri operacijah v trebušni votlini; 2972 bolnikov).
• without ‘ST segment elevation' (an abnormal reading on the electrocardiogram or ECG) in patients who are not going to undergo urgent angioplasty (within two hours): angioplasty or 
• brez „dviga spojnice ST“ (nenormalen izpis na elektrokardiogramu ali EKG) pri bolnikih, ki ne bodo prestali nujne angioplastike (v okviru dveh ur): angioplastika ali perkutana koronarna intervencija (PCI) je operacija za odpravo blokade srčnih krvnih žil,
At higher strengths (5, 7.5 and 10 mg), Quixidar is used to treat VTEs such as deep vein thrombosis (DVT, a blood clot in the leg) or pulmonary embolism (PE, blood clot in the lung). 
Zdravilo Quixidar v večjih jakostih (5, 7,5 in 10 mg) je mogoče uporabljati za zdravljenje tromboemboličnih dogodkov, kot npr. globoke venske tromboze (DVT, krvni strdek v nogi) ali pljučne embolije (PE, krvni strdek v pljučih).
Quixidar (1.5 and 2.5 mg strengths) is used to prevent venous thromboembolic events (VTEs, problems caused by blood clots) in patients who are having major surgery to their legs, such as a hip replacement or surgery to repair a knee or hip fracture. 
Zdravilo Quixidar (jakosti 1,5 in 2,5 mg) se uporablja za preprečevanje venskih tromboemboličnih dogodkov (VTE, zapletov, ki jih povzročajo krvni strdki) pri bolnikih po velikih operativnih posegih na nogah, kot so zamenjava kolka ali operativno zdravljenje kolena ali zloma kolka.
In the treatment of VTE, Quixidar was compared with enoxaparin (DVT: 2,192 patients) or with unfractionated heparin (PE: 2,184 patients). 
Pri zdravljenju venskih tromboemboličnih dogodkov so zdravilo Quixidar primerjali z enoksaparinom (globoka vensko tromboza: 2192 bolnikov) ali z nefrakcioniranim heparinom (pljučna embolija: 2184 bolnikov).
In the treatment of DVT or PE, the recommended dose is 7.5 mg once a day by subcutaneous injection, usually for seven days. 
Pri zdravljenju globoke venske tromboze ali pljučne embolije je priporočeni odmerek zdravila Quixidar 7,5 mg enkrat dnevno, ki se daje s subkutano injekcijo navadno sedem dni.
The full EPAR for Quixidar can be found here. 
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Quixidar je na voljo tukaj.
For patients with unstable angina or myocardial infarction, the recommended dose is 2.5 mg once daily by subcutaneous injection, but the first dose is given intravenously (into a vein) through an existing line or as an infusion (drip) in patients with ST segment elevation. 
Za bolnike z nestabilno angino pektoris ali miokardnim infarktom je priporočeni odmerek 2,5 mg enkrat dnevno s subkutano injekcijo, pri čemer se prvi odmerek daje intravensko (v veno) skozi obstoječo cevko ali kot infuzijo (kapalno infuzijo) pri bolnikih z dvigom spojnice ST. Z zdravljenjem se mora pričeti takoj po diagnozi in mora trajati do osem dni ali dokler bolnik ne odide iz bolnišnice.
How has Quixidar been studied? 
Kako je bilo zdravilo Quixidar raziskano?
What is Quixidar used for? 
Za kaj se zdravilo Quixidar uporablja?
How is Quixidar used? 
Kako se zdravilo Quixidar uporablja?
• with ‘ST segment elevation' in patients who are receiving thrombolytic medicines (‘clot busters') 
• z „dvigom spojnice ST“ pri bolnikih, ki prejemajo trombolitična zdravila („razkrojevalci strdkov clot busters“) ali ki niso pred prejemom katerega koli drugega zdravljenja za obnovitev krvnega pretoka v srce.
The first compared the effects of Quixidar with those of enoxaparin in over 20,000 patients with unstable angina or myocardial infarction without ST segment elevation, and the second compared Quixidar with standard care (unfractionated heparin in eligible patients, or placebo) in over 12,000 patients with myocardial infarction with ST segment elevation. 
V drugi študiji pa so primerjali učinke zdravila Quixidar s standardnim zdravljenjem (nefrakcioniranim heparinom pri ustreznih bolnikih ali s placebom) pri več kot 12.000 bolnikih z miokardnim infarktom z dvigom spojnice ST.
What is Quixidar? 
Kaj je zdravilo Quixidar?
Date of first authorisation: 17 January 2007 Date of latest renewal: 17 January 2012 
Datum prve odobritve: 17. januar 2007 Datum zadnjega podaljšanja: 17. januar 2012
(It is also better to avoid Imprida in early pregnancy, see Pregnancy section). 
(Zdravilu Imprida se je bolje izogibati tudi v zgodnji nosečnosti, glejte poglavje Nosečnost).
In two long-term follow-up studies the effect of Imprida was maintained for over one year. 
V dveh dolgoročnih spremljevalnih študijah se je učinek zdravila Imprida ohranil več kot eno leto.
Imprida with food and drink 
Zdravilo Imprida skupaj s hrano in pijačo
if you are allergic to valsartan or any of the other ingredients of this medicine (listed in section 6). 
če ste alergični na valsartan ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Your doctor will normally advise you to stop taking Imprida before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Imprida. 
Zdravnik vam bo praviloma svetoval, da prenehate z jemanjem zdravila Imprida še preden zanosite oziroma takoj, ko ugotovite da ste noseči in vam bo svetoval jemanje drugega zdravila namesto zdravila Imprida.
It is recommended to take Imprida with some water. 
Zdravilo Imprida je priporočljivo vzeti z malo vode.
Imprida and older people (age 65 years or over) Your doctor should exercise caution when increasing your dose. 
Zdravilo Imprida in starejši ljudje (stari 65 let ali več) Zdravnik mora biti pri zviševanju vašega odmerka previden.
Children and adolescents The use of Imprida in children and adolescents is not recommended (aged below 18 years old). 
Otroci in mladostniki Zdravila Imprida ni priporočljivo uporabljati pri otrocih in mladostnikih (starih manj kot 18 let).
Patients taking Imprida and driving vehicles or using machines should take into account that dizziness or weariness may occasionally occur. 
Bolniki, ki jemljejo zdravilo Imprida in vozijo motorna vozila ali uporabljajo stroje, morajo upoštevati, da se lahko občasno pojavi omotica ali utrujenost.
See also information under the heading “Do not take Imprida”. 
Glejte tudi informacije pod naslovom “Ne jemljite zdravila Imprida”.